Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 3, 2014, Pages 487-493

  Furuta, Takahisa ^a   Sugimoto, Mitsushige ^a   Kodaira, Chise ^a   Nishino, Masafumi ^b   Yamade, Mihoko ^a   Uotani, Takahiro ^a   Sahara, Shu ^a   Ichikawa, Hitomi ^a   Yamada, Takanori ^a   Osawa, Satoshi ^a   Sugimoto, Ken ^a   Watanabe, Hiroshi ^a   Umemura, Kazuo ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JA Shizuoka Kohseiren Enshu Hospital   (Japan)

Author keywords

Eradication; H. pylori; Sitafloxacin rescue regimen

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; ECABET; LEVOFLOXACIN; METRONIDAZOLE; RABEPRAZOLE; SITAFLOXACIN; UREA C 13;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; DUODENUM ULCER; ENDOSCOPIC SURGERY; ERADICATION THERAPY; FEMALE; GASTRITIS; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTENTION TO TREAT ANALYSIS; JAPAN; JAPANESE; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; METALLIC TASTE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAPID UREASE TEST; STOMACH; STOMACH BIOPSY; STOMACH CANCER; STOMACH ULCER; UNSPECIFIED SIDE EFFECT; UREA BREATH TEST;

ERADICATION; H. PYLORI; SITAFLOXACIN RESCUE REGIMEN;

ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; GASTRITIS; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; RABEPRAZOLE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84897669977     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12442     Document Type: Article

References (35)

1. Asaka M, Sugiyama T, Kato M etal. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 2001; 6: 254-261.
2. Murakami K, Sato R, Okimoto T etal. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment. Pharmacol. Ther. 2003; 17: 119-123.
3. Gisbert JP, Castro-Fernandez M, Bermejo F etal. Third-line rescue therapy with levofloxacin after two H.pylori treatment failures. Am. J. Gastroenterol. 2006; 101: 243-247.
4. Murakami K, Okimoto T, Kodama M etal. Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations. Antimicrob. Agents Chemother. 2009; 53: 3097-3099.
5. Matsuzaki J, Suzuki H, Nishizawa T etal. Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies. Antimicrob. Agents Chemother. 2012; 56: 1643-1645.
6. Murakami K, Furuta T, Ando T etal. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. J. Gastroenterol. 2013; 48: 1128-1135.
7. Shirai N, Furuta T, Moriyama Y etal. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment. Pharmacol. Ther. 2001; 15: 1929-1937.
8. Yasuda S, Horai Y, Tomono Y etal. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status. Clin. Pharmacol. Ther. 1995; 58: 143-154.
9. Saitoh T, Fukushima Y, Otsuka H etal. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment. Pharmacol. Ther. 2002; 16: 1811-1817.
10. Sugimoto M, Furuta T, Shirai N etal. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin. Pharmacol. Ther. 2004; 76: 290-301.
11. Furuta T, Shirai N, Xiao F etal. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H.pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology 2003; 50: 2274-2278.
12. Shirai N, Sugimoto M, Kodaira C etal. Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur. J. Clin. Pharmacol. 2007; 63: 743-749.
13. 13C-urea breath test in Japan. J. Gastroenterol. 1998; 33 (Suppl 10): 36-39.
14. Wang JT, Lin JT, Sheu JC etal. Detection of Helicobacter pylori in gastric biopsy tissue by polymerase chain reaction. Eur. J. Clin. Microbiol. Infect. Dis. 1993; 12: 367-371.
15. Furuta T, Soya Y, Sugimoto M etal. Rapid automated genotyping of CYP2C19 and Helicobacter pylori 23S rRNA gene in gastric juice. J. Gastroenterol. Hepatol. Res. 2013; 2: 508-512.
16. Sim SC, Risinger C, Dahl ML etal. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 2006; 79: 103-113.
17. Karczewska E, Klesiewicz K, Skiba I etal. Variability in prevalence of Helicobacter pylori strains resistant to clarithromycin and levofloxacin in Southern Poland. Gastroenterol. Res. Pract. 2012; 2012: 418010.
18. Bogaerts P, Berhin C, Nizet H, Glupczynski Y. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 2006; 11: 441-445.
19. Malfertheiner P, Megraud F, O'Morain CA etal. Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-664.
20. Schrauwen RW, Janssen MJ, de Boer WA. Seven-day PPI-triple therapy with levofloxacin is very effective for Helicobacter pylori eradication. Neth. J. Med. 2009; 67: 96-101.
21. Fock KM, Katelaris P, Sugano K etal. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J. Gastroenterol. Hepatol. 2009; 24: 1587-1600.
22. Hung KH, Sheu BS, Chang WL etal. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter 2009; 14: 61-65.
23. Chang WL, Sheu BS, Cheng HC etal. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J. Gastroenterol. Hepatol. 2009; 24: 1230-1235.
24. Miyachi H, Miki I, Aoyama N etal. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter 2006; 11: 243-249.
25. Yamade M, Sugimoto M, Uotani T etal. Resistance of Helicobacter pylori to quinolones and clarithromycin assessed by genetic testing in Japan. J. Gastroenterol. Hepatol. 2011; 26: 1457-1461.
26. Perna F, Zullo A, Ricci C etal. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig. Liver Dis. 2007; 39: 1001-1005.
27. Sanchez JE, Saenz NG, Rincon MR etal. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J. Antimicrob. Chemother. 2000; 46: 283-285.
28. Fujimura S, Kato S, Iinuma K, Watanabe A. In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children. J. Med. Microbiol. 2004; 53: 1019-1022.
29. Athamna A, Athamna M, Medlej B etal. In vitro post-antibiotic effect of fluoroquinolones, macrolides, beta-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis. J. Antimicrob. Chemother. 2004; 53: 609-615.
30. Hassan IJ, Stark RM, Greenman J, Millar MR. Absence of a post-antibiotic effect (PAE) of beta-lactams against Helicobacter pylori NCTC 11637. J. Antimicrob. Chemother. 1998; 42: 661-663.
31. Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol. Clin. North Am. 2010; 39: 465-480.
32. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. North Am. 2003; 17: 479-501.
33. Miehlke S, Kirsch C, Schneider-Brachert W etal. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003; 8: 310-319.
34. Furuta T, Sugimoto M, Kodaira C etal. The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of H.pylori. Hepatogastroenterology 2010; 57: 1314-1319.
35. Furuta T, Shirai N, Takashima M etal. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther. 2001; 69: 158-168.